AI summary by TwinMind
Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson
Andrew Huberman
2h 52m 5s
Introduction and Definitions
- Dr. Matthew Johnson directs Center for Psychedelic and Consciousness Research at Johns Hopkins
- Psychedelic definition: compounds that profoundly alter sense of reality and self
- Multiple pharmacological classes fall under "psychedelic" umbrella:
- Classic psychedelics (LSD, psilocybin, DMT, mescaline) - serotonin 2A receptor agonists
- NMDA antagonists (ketamine, PCP, dextromethorphan)
- Kappa-opioid agonists (Salvinorin A from Salvia divinorum)
- Entactogens (MDMA) - primarily serotonin release mechanism
Classic Psychedelics Mechanisms
- Two structural classes: tryptamine-based (psilocybin, DMT) and phenethylamine-based (LSD, mescaline)
- All act as serotonin 2A receptor agonists/partial agonists
- Differ from serotonin itself - chemistry doesn't always predict receptor effects
- Downstream effects include increased glutamate transmission
- Profoundly alter predictive models brain uses to navigate reality
Clinical Trial Process at Hopkins
- Extensive screening: psychiatric interviews, cardiovascular testing
- Exclusions: psychotic disorders, bipolar disorder, family history of these conditions
- 4-8 hours preparation with therapeutic guides
- Session day: 20-30mg psilocybin (pure compound, not mushrooms)
- No body weight adjustment needed (brain size doesn't vary significantly)
- Eye shades worn, supportive environment with guides present
- Cardiovascular monitoring throughout (blood pressure, pulse every 30 minutes)
- Integration session next day after writing about experience
Therapeutic Approach and Mechanisms
- "Letting go" central to therapeutic process - surrendering control vs. trying to maintain it
- Bad trips occur in ~1/3 of high-dose sessions even with preparation
- Gateway between challenging experience and transcendental mystical experience
- Changes in self-representation appear to be key therapeutic mechanism
- Persistent effects lasting months to over a year
- "Duh experiences" - profound sense of agency and ability to change
MDMA Differences
- Synthetic compound, increases both serotonin and dopamine release
- Less likely to cause challenging experiences compared to classic psychedelics
- Particularly effective for PTSD - reduces amygdala reactivity
- Allows reprocessing of traumatic memories without fight-or-flight response
- Currently approved as Spravato (esketamine) but not treated as psychedelic therapy
Safety Considerations and Risks
- Two main dangers: psychiatric predisposition and bad trips in unsafe environments
- Rare cases of prolonged psychiatric issues in vulnerable individuals
- HPPD (hallucinogen-persisting perceptual disorder) very rare, never seen in clinical trials
- May be related to rare neurological susceptibility, not specific to psychedelics
- Flashbacks often state-dependent learning or brief perceptual anomalies
Microdosing
- ~1/10th of psychedelic dose (1mg psilocybin, 10-20 micrograms LSD)
- Claims: better focus (Adderall alternative), antidepressant effects
- No peer-reviewed studies show cognitive enhancement or sustained mood improvement
- Some studies show slight impairment in time estimation
- Potential concern: chronic 5-HT2B receptor activation could cause heart valve problems
- More research needed on specific dosing protocols advocated by enthusiasts
Age and Development
- FDA pushing for pediatric studies despite no current research
- Concerns about developing brain susceptibility vs. increased plasticity
- Treatment-resistant cases in adolescents may be first targets
- Age 25 inflection point for neural plasticity, but individual variation exists
Legal Status and Future
- Currently Schedule I federally, but state/local decriminalization varies
- Oregon state-level legalization of psilocybin therapy in development
- MDMA likely FDA-approved for PTSD within 3 years in clinical settings
- Psilocybin breakthrough therapy designation for depression
- Medical development separate from decriminalization efforts
- Future regulation model may require training/licensing rather than criminalization
Traumatic Brain Injury Research
- Exploratory work with UFC fighters and retired athletes
- Anecdotal reports of cognitive improvement after psychedelic use
- Animal studies show neural plasticity: dendritic growth, new connections
- Targeting depression in TBI patients with secondary aim of cognitive improvement
- MRI studies to assess gray matter changes over time
Funding and Academic Support
- Primarily philanthropic funding: Heffter Research Institute, Beckley Institute, Council on Spiritual Practices
- $17 million gift from Cohen Foundation and Tim Ferriss collaborative created center
- Limited NIH/NIDA funding only for abuse liability studies
- Breakthrough therapy designations worth millions in pharmaceutical development
- Academic freedom to focus on therapeutic applications rather than abuse potential
